Larkspur Biosciences to Present Breakthrough Innovations at the 2023 BIO International Convention

Larkspur Biosciences Unveils Cutting-Edge Discoveries at the 2023 BIO International Convention

Larkspur Biosciences is building the next precision immunotherapies to outsmart cancer. Larkspur’s approach targets the unique ways that tumors hijack the immune system by developing precision immunotherapies for molecularly defined patient populations in order to overcome these bottlenecks. The company is advancing its first-in-class programs to outsmart the tumor and enable robust and sustained immune responses in colorectal cancer (CRC) and beyond. LarkX, the company’s discovery platform, leverages tumor genetics and immune phenotypes from patient-derived data to fuel its pipeline and offers the opportunities to address multiple types of cancer.

Larkspur is a company focused on developing innovative approaches to target the ways in which tumors manipulate the immune system. The company has a range of programs aimed at disrupting tumor immune evasion and enhancing the body's immune response against cancer. One of Larkspur's lead programs involves a cutting-edge approach to lipid remodeling. This approach aims to "uncloak" tumors by targeting the alterations in lipid metabolism that occur within cancer cells. By disrupting these lipid changes, Larkspur aims to expose the tumors to the immune system, making them more vulnerable to immune attack. Larkspur Biosciences, a biotechnology company building the next precision immunotherapies to outsmart cancer, announced that they will be participating in the 2023 BIO International Convention being held June 5-8 at the Boston Convention & Exhibit Center, Boston, MA.

The Larkspur team will be meeting with potential strategic partners and collaborators to discuss how their approach targets the unique ways that tumors hijack the immune system. This includes the company’s lead program, a cutting-edge approach to lipid remodeling to uncloak tumors, as well as its first-in-class program targeting Pin1, a key mechanism of fibroblast differentiation to activate immune cells. Larkspur is also actively seeking partners for our first-in-class B cell checkpoint antibody program.

Published on : 31st May, 2023